


6. A compound according to any one of the preceding claims wherein R^1 is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

7. A compound according to any one of the preceding claims where X is CH_2 .

8. A process for preparing a compound according to claim 1 which process comprises either

(a) where R^4 is $NHCO R^{15}$ or $NHSO_2 R^{15}$, reacting a compound of formula (VII)



(VII)


where X, R^1 , R^3 , R^5 , R^6 and R^7 are as defined in claim 1, and R^2 is a group R^2 as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)

where Z is a leaving group and R^{22} is a group COR^{15} or $SO_2 R^{15}$ where R^{15} is group R^{15} as defined in relation to formula (I) or a precursor thereof;

or (b) where R^4 is a group $OCONR^{16}R^{17}$, reacting a compound of formula (VIIA)



(VIIA)

where X, R^{2'}, R¹, R³, R⁵, R⁶ and R⁷ are as defined claim 1 and R² is a group R² as defined in claim 1 or a protected form thereof, with a compound of formula (VIII A)



(VIII A)

where Z, R¹⁶ and R¹⁷ are as defined above;

and thereafter if desired or necessary:

(i) converting a precursor group R^{15'} to a group R¹⁵ and/or converting a group R¹⁵ to a different such group;

(ii) deprotecting a group R^{2'} to a group R².

9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 in combination with a pharmaceutically acceptable carrier.

10. A compound according to any one of claims 1 to 7 for use in the preparation of a medicament for use in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.

FOR UTILITY DESIGN
CIP/PCT NATIONAL PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONS

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PW
FORM
Z70471/IUST

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED ANTI-FLAMMATORY INDOLE-DERIVATIVES

the specification of which (CHECK applicable BOX(ES))

X ☐ A. ☐ is attached hereto.
BOX(ES) ☒ B. ☐ was filed on _____ as U.S. Application No. _____

☒ C. ☐ was filed as PCT International Application No. PCT/GB00/00260 on 31st January 2000 and (if applicable to U.S. or PCT application) was amended on _____ I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to Patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 1.19(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S)	Date first laid-open or published	Date Patented or Granted	Priority NOT Claimed
Number	Country	Day/MONTH/Year filed	
9902469.8	United Kingdom	05.02.1999	

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(a) or 120 and/or 365(c) of the indicated United States applications listed below and PCT international applications listed above and below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to Patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NON PROVISIONAL AND/OR PCT APPLICATION(S)	Status	Priority NOT Claimed
Application No. (series code/serial no.)	Day/MONTH/Year Filed	
	Pending, abandoned, patented	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop LLP, Intellectual Property Group, telephone number (202) 861-3000 (to whom all communications are to be directed), and persons of that firm who are associated with USPTO Customer No. 909 (see below label) individually and collectively my attorney to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete from that Customer No. names of persons no longer with their firm, to add new persons of their firm to that Customer No., and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above firm and/or an attorney of that firm in writing to the contrary.

00909

(1) INVENTOR'S SIGNATURE

Date: 19/9/01

Name	ALLAN W. FAUL	
First	Middle Initial	Family Name
Residence	MACCLESFIELD CHESHIRE	UNITED KINGDOM
City	State/Foreign Country	Country of Citizenship
Mailing Address	AstraZeneca UK LTD Alderley Park Macclesfield Cheshire SK10 4TG United KINGDOM	
(include Zip Code)		

(2) INVENTOR'S SIGNATURE

Date: 21/9/01

Name	JASON KETTLE	
First	Middle Initial	Family Name
Residence	MACCLESFIELD CHESHIRE	UNITED KINGDOM
City	State/Foreign Country	Country of Citizenship
Mailing Address	AstraZeneca UK LTD Alderley Park Macclesfield Cheshire SK10 4TG United KINGDOM	
(include Zip Code)		

☐ OR ADDITIONAL INVENTORS see attached page.

☐ See additional foreign, Priorities on attached page (incorporated herein by reference).

Atty Dkt. No. P (M#)